- Why should you buy this report?
- Develop and design your in-licensing and out-licensing strategies by analysing the oncology biosimilar landscape
- Gain an understanding of market potential and current regulatory outlook shaping the oncology biosimilars landscape in key markets
- Learn about expert and high prescriber perceptions of biosimilars in the pharma industry
In oncology, biosimilar versions of six biologic drugs are available. The EMA has pioneered regulatory acceptance of biosimilars, and approved more biosimilars than the FDA. Beyond the major markets of the US and 5EU (France, Germany, Italy, Spain and UK), two emerging markets are key in the oncology biosimilars space: India, with the most approved biosimilars worldwide, and South Korea, which is home to major biosimilar developer Celltrion.
GlobalData’s Biosimilar market report takes a deep dive into the oncology biosimilars landscape in the 9 major markets, including an analysis of market potential, current and anticipated use of biosimilars, clinical and commercial concepts, important indications, and an overview of both leading and emerging developers. GlobalData anticipates that biosimilars will represent an important subset of this biologic-centered pharmaceutical market in years to come.